Compare PTGX & CBC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PTGX | CBC |
|---|---|---|
| Founded | 2006 | 1902 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4B | 5.2B |
| IPO Year | 2016 | N/A |
| Metric | PTGX | CBC |
|---|---|---|
| Price | $98.65 | $27.19 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 6 |
| Target Price | ★ $108.23 | $28.67 |
| AVG Volume (30 Days) | 564.9K | ★ 591.2K |
| Earning Date | 05-07-2026 | 04-28-2026 |
| Dividend Yield | N/A | ★ 2.21% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $874.25 | $12.15 |
| Revenue Next Year | N/A | $6.34 |
| P/E Ratio | $2,057.40 | ★ $14.38 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $44.15 | $22.50 |
| 52 Week High | $107.84 | $27.81 |
| Indicator | PTGX | CBC |
|---|---|---|
| Relative Strength Index (RSI) | 46.98 | 69.70 |
| Support Level | $95.40 | $23.28 |
| Resistance Level | $100.00 | N/A |
| Average True Range (ATR) | 4.41 | 0.69 |
| MACD | -0.30 | 0.04 |
| Stochastic Oscillator | 16.58 | 79.55 |
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.
Central Bancompany Inc is a bank holding company that provides a broad range of retail, corporate, mortgage banking, wealth management, and trust products and services to individuals and businesses.